

Thyrocare launches “FocusTB”, its affordable TB diagnostics brand

<https://www.biovoicenews.com/thyrocare-launches-focus-tb-affordable-tb-diagnostics-brand/>

By : BioVoice Correspondent - January 3, 2018



New Delhi: Thyrocare technologies Limited (Thyrocare) has announced the launch of “FocusTB”, its affordable brand focusing on TB diagnostics.

Commenting on the launch, Dr A Velumani, CEO of the company mentioned, “With the launch of our TB offering, we hope to make a fundamental and measurable change to the way Tuberculosis is diagnosed and treated in India. Drug-resistant strains of TB pose a significant public health hazard and must be addressed by India’s healthcare sector sooner than later. We are bringing highly advanced technologies like PCR to bear against this adversary for the first time in India. FocusTB services are available throughout India through Thyrocare’s Pan Asian network with more than 30,000 sample collection points.”

Thyrocare is India’s first fully automated diagnostics services provider with a focus on

providing quality at affordable costs to laboratories and hospitals in India and other countries. Thyrocare operates its national Centralized Processing Laboratory (CPL) in Mumbai – India for esoteric tests, and Regional Processing Laboratories in major metro cities of India and other parts of Asia. Thyrocare Technologies operates in high growth segment of pathology (94 percent of FY17 revenue) and imaging (6 percent of FY17 revenue). The company focuses on preventive care and human body disorders and offers 198 tests in among various categories.

India has among the highest incidences of Tuberculosis (TB) globally and hence diagnosis and treatment of the same are very important. Estimates suggest that as much as 40 percent of the Indian population suffers from Latent TB rather than the active form of the disease, which is contracted when the patient is immuno-compromised.